

Galunisertib

Catalog No: tcsc0474



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg



Specifications

CAS No:

700874-72-2

Formula:

$C_{22}H_{19}N_5O$

Pathway:

TGF-beta/Smad

Target:

TGF- β Receptor

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 47 mg/mL (127.23 mM)

Alternative Names:

LY2157299

Observed Molecular Weight:

369.42


Product Description

Galunisertib (LY2157299) is a selective **TGF-β** receptor inhibitor with an **IC₅₀** of 56 nM.

IC50 & Target: IC50: 56 nM (TGF-βR)^[1]

In Vitro: Galunisertib (LY2157299) is a selective ATP-mimetic inhibitor of TGF-β receptor (TβR)-I activation LY2157299 (0.1, 1, 10, and 100 μM) displays a slight dose-dependent potentiation of Sorafenib in SK-Sora, HepG2, and Hep3B cell lines but not in JHH6, SK-HEP1, and HuH7 cell lines^[2].

In Vivo: Human xenografts Calu6 (non-small cell lung cancer) and MX1 (breast cancer) are implanted subcutaneously in nude mice. After oral administration of 75 mg/kg, Galunisertib (LY2157299) induces a 70% decrease in pSmad for both types of cell lines. The time at which pSmad recovered 80% of baseline is approximately 6 h after administration^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!